Accountable care organizations (ACOs) are legal entities that are responsible for the cost, quality, and care of a population of patients. ACOs are part of the Shared Savings Program of Medicare under the Affordable Care Act.
Erlotinib (Tarceva) has a low response rate in non–small cell lung cancer (NSCLC) but does improve survival in a subpopulation of patients harboring a wild-type (wt) epidermal growth factor receptor (EGFR) gene.
“Hallmarks of Cancer”, published in the journal Cell in 2000 provided a conceptual framework for the evolution of cancer as well as an all-encompassing review of the cancer field to date. The article is updated in the March 4th, 2011 issue of Cell.
The Journal of Clinical Oncology published a paper ahead of print on March 21, 2011 that shows no increased risk of venous thromboembolisms (VTEs) when bevacizumab was added to chemotherapy compared to chemotherapy alone.
The National Comprehensive Cancer Network presented the first treatment algorithm for post-transplant lymphoproliferative disorder (PTLD) at the 16th annual NCCN's Conference on Clinical Practice Guidelines and Quality.
As we learn more about the network of cellular pathways that function in the proliferation of cancer cells, it is becoming abundantly clear that there is no “magic bullet” cancer treatment. Janet Woodcock highlights the goals and current developments at the FDA to progress the combination clinical trial process